NCT07458022Active, not recruitingPhase 2
MAGNESIUM & SSRI VS SSRI ALONE AMONG PATIENTS OF MAJOR DEPRESSIVE DISORDER
Source: ClinicalTrials.gov · Last updated 9 Mar 2026
Brief summary (registry, in English)
Role of Magnesium in Depressive Disorder
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 3 Mar 2026
- Start date
- 1 Dec 2025
- Primary completion date
- Apr 2026
- Lead sponsor
- University of Child Health Sciences and Children's Hospital, Lahore
- Diseases
- Depression
- NCT number
- NCT07458022
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 50
- From 1 Dec 2025 to the primary completion date, Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals who recently underwent treatment with electroconvulsive therapy, have a history of epilepsy or other severe neurological problems, have experienced a head injury, are cognitively impaired, and have comorbid conditions such as liver, renal, cardiovascular, neurological, or endocrine, or respiratory problems, or are pregnant or nursing mothers
Who the study is looking for
- All patients of above 18 years diagnosed with DSM who had MDD and receiving SSRI alone and SSRI plus magnesium.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Combined Military Hospital (CMH) Coordinator of this site? Confirm its status | Multan | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.